Cycle Pharmaceuticals

Specialty pharmaceutical company focused on rare diseases, founded in 2012 in Cambridge, UK. Works in three areas: improving existing orphan drugs, reinstating previously marketed drugs, and extending medicines to new medical areas with academic partners. Lead product: NITYR® (nitisinone), FDA-approved for Hereditary Tyrosinemia Type 1. Also has offices in Boston, MA.